Mostrar el registro sencillo del ítem

Chemotherapy-induced neuropathic pain characteristics in Mexico's National Cancer Center pain clinic

dc.creatorCoffeen, Uliseses_ES
dc.creatorSotomayor-Sobrino, Marco Antonioes_ES
dc.creatorJiménez-González, Ariadnaes_ES
dc.creatorBalcazar-Ochoa, Luis Gerardoes_ES
dc.creatorHernández-Delgado, Pamelaes_ES
dc.creatorFresán, Anaes_ES
dc.creatorPlancarte-Sanchez, Ricardoes_ES
dc.creatorArias-Muñoz, Samantha Danielaes_ES
dc.creatorOchoa-Aguilar, Abrahames_ES
dc.date2019
dc.date.accessioned2022-12-14T17:49:04Z
dc.date.available2022-12-14T17:49:04Z
dc.date.issued2019
dc.identifierJC29NC22es_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/7653
dc.identifier.urihttps://doi.org/10.2147/JPR.S186107
dc.descriptionIntroduction: Chemotherapy (CT) is one of the most commonly used pharmacological approaches in cancer treatment. However, CT induces damage to several tissues causing significant deleterious effects in cancer survivors being chemotherapy-induced neuropathic pain (CINP) among the most commonly reported. CINP is thought to be present in up to 68.1% of the patients within 1 month of receiving CT. Due to the fact that reliable statistic information is scarce in several Latin American countries' diagnosis and treatment of this side-effect may be delayed directly affecting patients. Therefore, the aim of the present study was to determine and present the incidence and features of CINP in patients with cancer attending the Pain Management Clinic at Mexicos' National Institute of Cancerology in Mexico City. Methods: We performed a retrospective, file-based analysis of all the patients treated in the Pain Management Clinic at the National Institute at Cancer in Mexico from January 2016 to January 2017. Results: CINP was found in 30.9% of the patients. The basal VAS was on average 2.5 upon arrival to the Pain Management Unit and 2.4 at the end of treatment (p>0.05). The patients with the highest risk of developing CINP were those treated with paclitaxel Odds ratio 8.3 (p<0.01), followed by platins OR 4 (p<0.01), vincristine OR 1.5 (p=0.01) and thalidomide OR 1.1 (p=0.01). Conclusion: Incidence of CINP was similar to previous reports; however, the number of variables related to this type of pain in our cohort may open a new line of research and highlight the importance of this particular issue to our health system. It is necessary to develop a mechanism to predict the risk of patients to suffer CINP and to search the mechanism to control and reduce the suffering related to the current treatments.es_ES
dc.formatPDFes_ES
dc.language.isoenges_ES
dc.publisherDove Medical Presses_ES
dc.relation12:1331-1339
dc.rightsAcceso Cerradoes_ES
dc.titleChemotherapy-induced neuropathic pain characteristics in Mexico's National Cancer Center pain clinices_ES
dc.typeArtículoes_ES
dc.contributor.affiliationLaboratorio de Neurofisiología Integrativa. Investigaciones en Neurociencias y División de Investigación Clínica, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Clinical Research Division, Mexico City, Mexico
dc.contributor.emailAbraham.ochoa@hll.com.mx (Abraham Ochoa-Aguilar)
dc.relation.jnabreviadoJ PAIN RES
dc.relation.journalJournal of Pain Research
dc.identifier.placeNueva Zelanda
dc.date.published2019
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
dc.identifier.eissn1178-7090
dc.identifier.doi10.2147/JPR.S186107
dc.subject.kwPain
dc.subject.kwChemotherapy
dc.subject.kwNeuropathy
dc.subject.kwPaclitaxel


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem